Anti-PGP9.5 antibody (ab72911)
- Product nameAnti-PGP9.5 antibodySee all PGP9.5 primary antibodies ...
- DescriptionMouse monoclonal to PGP9.5
- Tested applicationsIHC-Fr, IHC-P, WB, ICC/IF more details
- Species reactivityReacts with: Mouse, Rat, Cow, Human
Recombinant full length human PGP9.5 purified from E. coli.
- Positive controlRat hippocampal cell homogenate and rat spinal cord tissue.
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
- Storage bufferPreservative: 10mM Sodium Azide
Constituents: Tissue culture supernatant
- PurityTissue culture supernatant
- Clonality Monoclonal
- Research Areas
Our Abpromise guarantee covers the use of ab72911 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IHC-P: Use at an assay dependent dilution.
IHC-Fr: Use at an assay dependent dilution.
WB: 1/5000. Detects a band of approximately <43 kDa (predicted molecular weight: 25 kDa).
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
- FunctionUbiquitin-protein hydrolase involved both in the processing of ubiquitin precursors and of ubiquitinated proteins. This enzyme is a thiol protease that recognizes and hydrolyzes a peptide bond at the C-terminal glycine of ubiquitin. Also binds to free monoubiquitin and may prevent its degradation in lysosomes. The homodimer may have ATP-independent ubiquitin ligase activity.
- Tissue specificityFound in neuronal cell bodies and processes throughout the neocortex (at protein level). Expressed in neurons and cells of the diffuse neuroendocrine system and their tumors. Weakly expressed in ovary. Down-regulated in brains from Parkinson disease and Alzheimer disease patients.
- Involvement in diseaseDefects in UCHL1 are the cause of Parkinson disease type 5 (PARK5) [MIM:613643]; also known as Parkinson disease autosomal dominant 5. PARK5 is a complex neurodegenerative disorder with manifestations ranging from typical Parkinson disease to dementia with Lewy bodies. Clinical features include parkinsonian symptoms (resting tremor, rigidity, postural instability and bradykinesia), dementia, diffuse Lewy body pathology, autonomic dysfunction, hallucinations and paranoia.
- Sequence similaritiesBelongs to the peptidase C12 family.
- Cellular localizationCytoplasm. Endoplasmic reticulum membrane. About 30% of total UCHL1 is associated with membranes in brain.
- Gracile axonal dystrophy antibodyNeuron cytoplasmic protein 9.5 antibodyOTTHUMP00000218137 antibody
- OTTHUMP00000218139 antibodyOTTHUMP00000218140 antibodyOTTHUMP00000218141 antibodyPark 5 antibodyPARK5 antibodyPGP 9.5 antibodyPGP9.5 antibodyPGP95 antibodyProtein gene product 9.5 antibodyUbiquitin C terminal esterase L1 antibodyUbiquitin C terminal hydrolase (neuron specific) antibodyUbiquitin C terminal hydrolase antibodyUbiquitin carboxyl terminal esterase L1 antibodyUbiquitin carboxyl terminal hydrolase isozyme L1 antibodyUbiquitin carboxyl-terminal hydrolase isozyme L1 antibodyUbiquitin thioesterase L1 antibodyUbiquitin thiolesterase antibodyUbiquitin thiolesterase L1 antibodyUCH L1 antibodyUCH-L1 antibodyUCHL 1 antibodyUCHL1 antibodyUCHL1_HUMAN antibody
Anti-PGP9.5 antibody images
Anti-PGP9.5 antibody (ab72911) at 1/5000 dilution + rat hippocampal homogenate
Predicted band size : 25 kDa
Observed band size : <43 kDa (why is the actual band size different from the predicted?)
ab72911 at 1/500 dilution staining PGP9.5 in rat spinal cord by Immunofluorescence (shown in red). Anti-neurofilament NF-H antibody staining is shown in green. The large cells are a-motorneurons and PGP9.5 fills the cytoplasm of their perikarya and dendrites.
References for Anti-PGP9.5 antibody (ab72911)
This product has been referenced in:
- Verkerk AO et al. Functional Nav1.8 channels in intracardiac neurons: the link between SCN10A and cardiac electrophysiology. Circ Res 111:333-43 (2012). Read more (PubMed: 22723301) »
- Siman R et al. Evidence that a Panel of Neurodegeneration Biomarkers Predicts Vasospasm, Infarction, and Outcome in Aneurysmal Subarachnoid Hemorrhage. PLoS One 6:e28938 (2011). WB ; Human . Read more (PubMed: 22174930) »